Darbepoetin alfa for Cancer-Related Anaemia
Author Information
Author(s): Glaspy J A, Jadeja J S, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian N S, Armstrong S, O'Byrne J, Rossi G, Colowick A B
Hypothesis
Can darbepoetin alfa alleviate anaemia in cancer patients undergoing chemotherapy?
Conclusion
Darbepoetin alfa is safe and effective in increasing haemoglobin levels in cancer patients receiving chemotherapy.
Supporting Evidence
- Darbepoetin alfa increased the proportion of patients with a haemoglobin response.
- The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa.
- Higher doses of darbepoetin alfa led to faster haemoglobin responses.
- No antibodies to darbepoetin alfa were detected in patients.
- Patients receiving darbepoetin alfa had similar completion rates of treatment compared to those receiving epoetin alfa.
Takeaway
This study shows that a medicine called darbepoetin alfa can help cancer patients who are feeling tired because of low blood levels.
Methodology
Patients were randomized to receive either darbepoetin alfa or epoetin alfa during chemotherapy, with safety and efficacy assessed through various haematologic endpoints.
Potential Biases
Potential bias due to the exclusion of patients with certain types of anaemia and the inability to adjust doses for non-responders.
Limitations
The study design did not allow for direct comparison of darbepoetin alfa and epoetin alfa due to fixed dosing without dose escalation for non-responders.
Participant Demographics
Patients were at least 18 years old, had solid tumours, and were anaemic with an Eastern Cooperative Oncology Group performance status of 0 to 2.
Statistical Information
Confidence Interval
95% confidence limits
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website